Laboratorio Reig Jofre S.A - Asset Resilience Ratio
Laboratorio Reig Jofre S.A (RJF) has an Asset Resilience Ratio of 0.72% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Laboratorio Reig Jofre S.A (RJF) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Laboratorio Reig Jofre S.A's Asset Resilience Ratio has changed over time. See Laboratorio Reig Jofre S.A balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Laboratorio Reig Jofre S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Laboratorio Reig Jofre S.A (RJF) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.54 Million | 0.72% |
| Total Liquid Assets | €2.54 Million | 0.72% |
Asset Resilience Insights
- Limited Liquidity: Laboratorio Reig Jofre S.A maintains only 0.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Laboratorio Reig Jofre S.A Industry Peers by Asset Resilience Ratio
Compare Laboratorio Reig Jofre S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
SHE:000766 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479 |
Drug Manufacturers - Specialty & Generic | 0.03% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Laboratorio Reig Jofre S.A (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Laboratorio Reig Jofre S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.62% | €5.59 Million ≈ $6.53 Million |
€344.85 Million ≈ $403.17 Million |
+1.37pp |
| 2023-12-31 | 0.25% | €830.00K ≈ $970.36K |
€330.55 Million ≈ $386.45 Million |
+0.12pp |
| 2022-12-31 | 0.13% | €429.00K ≈ $501.55K |
€321.19 Million ≈ $375.51 Million |
-1.45pp |
| 2021-12-31 | 1.59% | €5.16 Million ≈ $6.03 Million |
€324.98 Million ≈ $379.93 Million |
-2.10pp |
| 2020-12-31 | 3.69% | €11.69 Million ≈ $13.67 Million |
€317.15 Million ≈ $370.78 Million |
+3.62pp |
| 2019-12-31 | 0.07% | €213.00K ≈ $249.02K |
€313.62 Million ≈ $366.65 Million |
-0.02pp |
| 2018-12-31 | 0.09% | €202.02K ≈ $236.18K |
€219.68 Million ≈ $256.82 Million |
-0.28pp |
| 2017-12-31 | 0.38% | €766.41K ≈ $896.01K |
€203.34 Million ≈ $237.72 Million |
+0.36pp |
| 2016-12-31 | 0.02% | €38.51K ≈ $45.03K |
€205.63 Million ≈ $240.41 Million |
0.00pp |
| 2015-12-31 | 0.02% | €35.74K ≈ $41.78K |
€187.05 Million ≈ $218.69 Million |
-2.38pp |
| 2014-12-31 | 2.40% | €4.34 Million ≈ $5.07 Million |
€180.74 Million ≈ $211.31 Million |
+1.72pp |
| 2014-09-30 | 0.68% | €597.44K ≈ $698.47K |
€87.41 Million ≈ $102.19 Million |
-0.29pp |
| 2013-12-31 | 0.97% | €816.00K ≈ $953.99K |
€83.77 Million ≈ $97.93 Million |
-14.88pp |
| 2012-12-31 | 15.85% | €15.54 Million ≈ $18.17 Million |
€98.06 Million ≈ $114.64 Million |
-34.20pp |
| 2011-12-31 | 50.06% | €82.78 Million ≈ $96.78 Million |
€165.38 Million ≈ $193.34 Million |
+49.60pp |
| 2010-12-31 | 0.45% | €828.00K ≈ $968.02K |
€183.09 Million ≈ $214.05 Million |
+0.33pp |
| 2009-12-31 | 0.12% | €246.00K ≈ $287.60K |
€200.18 Million ≈ $234.03 Million |
-1.06pp |
| 2006-12-31 | 1.18% | €3.41 Million ≈ $3.99 Million |
€288.98 Million ≈ $337.84 Million |
+0.91pp |
| 2005-12-31 | 0.27% | €420.00K ≈ $491.02K |
€156.40 Million ≈ $182.84 Million |
-- |
About Laboratorio Reig Jofre S.A
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmacy, food, and animal food. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables … Read more